Larimar Pharma - LRMR EV/EBITDA Multiple

Corporate emblem and logo of Larimar Pharma (LRMR)

The price action for Larimar Therapeutics (LRMR) available on the GURU.Markets chart helps assess the effectiveness of management, which transparently conducts drug development and engages with the FDA. The current indicator is 0.00. The biotech startup's financial stability depends on external capital, as commercial revenue is absent. Meanwhile, the success of trials for the treatment of Friedreich's ataxia strengthens the confidence of investors and specialized communities.

LRMR (Larimar Pharma) EV/EBITDA Multiple history from 11/23/2025 to 11/12/2026

LRMR (larimartx.com): analytical breakdowns and indicator data

- market price and analyst price targets:
Price Chart Larimar Pharma|LRMR - Broker Consensus Forecast
- issuer market value details:
Market Capitalization Larimar Corp|LRMR - Total Enterprise Value
- issuer book value statistics:
Accounting Value per Share Larimar Therapeutics|LRMR - Book Capitalization|Market Value to Book Value Ratio larimartx.com|LRMR - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Larimar Therapeutics|LRMR - Long-Term Liabilities to Capital|Short-Term Debt to Equity Larimar Therapeutics, Inc.|LRMR - Company Debts|Debt to Book Capitalization Ratio Larimar Corp|LRMR - Long-Term Debt|Company Short-Term Debts Larimar Therapeutics|Quick Liquidity Indicator larimartx.com
- net income and valuation multiples indicators:
LRMR - Company Net Income|Expected Profit Larimar Therapeutics|LRMR - Price to Earnings Ratio|Forward P/E Multiple Larimar Therapeutics|LRMR - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Larimar Corp|LRMR - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Larimar Therapeutics|LRMR - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months larimartx.com|LRMR - Net earnings per share growth this year|Earnings growth forecast for next year Larimar Therapeutics
Summary company analytics:LRMR (Larimar Pharma)
Original product of Larimar Therapeutics, Inc.

This indicator determines the real value of the business by combining market capitalization with net debt relative to operating profit. An increase in the metric signals inflated market expectations, while a decrease indicates undervalued assets. By analyzing the EV/EBITDA value of the business, an investor can see the capitalization efficiency of expenditures on laboratory robotics and AI protein simulations. The automation of routine processes at Larimar Therapeutics (LRMR) directly impacts future margins, which is reflected in the dynamics of this multiple.

Competitor analysis

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jazz Pharma JAZZ|CYTK: Enterprise Value to Operating Income Before Depreciation|PTC Therapeutics, Inc. - EV/EBITDA Multiple|Company Value to EBITDA scholarrock.com|CNTA (Centessa) - Enterprise Value to EBITDA Ratio|Dyne Therapeutics Inc (DYN) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Edgewise Pharma|RAPP: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alumis Inc. (ALMS)|ZVRA - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Contineum Therapeutics CTNM|Capricor Therapeutics Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TRDA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Channel Pharma|MNOV: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple serinatherapeutics.com SER|Enterprise Value to EBITDA Ratio BTAI|Company Value to EBITDA ProMIS PMN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Apimeds Pharmaceuticals (APUS)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization AEON (aeonbiopharma.com)|EV/EBITDA Multiple NLSP (NLS Pharmaceutics)|EV/EBITDA Multiple Bionomics Ltd. BNOX|HUGE - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation RETA (Reata Pharmaceuticals Inc)